ArticlePloS one2025
Chemical nucleases are a robust alternative for RNase H cleavage of human ribosomal RNA.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Click Conjugates of Artificial Ribonucleases: Sequence Specific Cleavage with Multiple Turnover.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Besides the abundant ribosomal and transfer RNA transcripts (rRNA and tRNA, respectively), there are tens of thousands of long coding (mRNA) and non-coding transcripts (lncRNA) within each cell whose modification profiles have not yet been elucidated. One reason for this is that most mRNAs and lncRNAs are low abundant and their purification prior to direct modification analysis by mass spectrometry (LC-MS) is highly challenging. State-of-the-art mRNA purification protocols are based on poly(A) enrichment with subsequent rRNA depletion using either magnetic pulldown assays or RNase H. While these methods are well suited for RNA sequencing, where residual rRNA content can be acceptable, LC-MS analysis of mRNA requires samples with less than 1% rRNA and higher yields, making the existing methods close to unaffordable. Thus, a new principle for low-cost (pre)mRNAs and lncRNAs preparation from total RNA will be beneficial for LC-MS analysis but also sequencing approaches. Here, we show that the use of ARRR (artificial ribosomal RNA remover: conjugates of standard DNA probes and a small-molecule chemical nuclease) is suitable for rRNA cleavage. In addition, ARRR has a higher target specificity compared to E. coli RNase H using regular DNA probes and only limited off-target RNA degradation is observed with ARRR. In summary, we present a promising tool with high potential to remove overly abundant rRNA, which might be used for enrichment of lncRNAs and (pre)mRNAs for downstream sequencing and MS-based analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.